Associate Director, Clinical Biomarkers (Oncology)

BeOne Medicines; United States; On-site; USD 147,000 - 197,000; Full time

Benefits offered by this job

Equity awards

Employee Stock Purchase Plan

Comprehensive benefits

Job summary

BeOne Medicines is seeking an Associate Director of Clinical Biomarker & Translational Medicine for Oncology (Solid Tumor Portfolio, GI franchise) to lead biomarker strategies across our clinical programs.

You will oversee assay development, trial biomarkers, and regulatory contributions while mentoring teams and collaborating with external partners to accelerate oncology drug development.

Qualifications

• PhD or MD/PhD in a relevant scientific discipline with 5+ years in pharma/biotech biomarker science in oncology.
• Deep expertise in biomarker discovery, clinical assay development, and validation for oncology trials.
• Proven leadership in translational medicine with biomarker strategies leading to regulatory milestones.

Responsibilities

• Lead global clinical biomarker strategy for solid tumor oncology with cross-functional teams.
• Oversee biomarker assay development, design input, and analytical/clinical validation.
• Analyze biomarker data to inform go/no-go decisions and trial progression.
• Communicate biomarker insights to internal and external stakeholders to shape strategy.
• Drive external partnerships with academia, CROs, and industry to advance biomarker programs.

Skills

Biomarker strategy

Clinical biomarker development

Translational medicine leadership

Cross-functional collaboration

Regulatory submissions

Publications / regulatory contributors

Mentoring / team leadership

Education

PhD or MD/PhD

Job description

BeOne Medicines is seeking an Associate Director of Clinical Biomarker & Translational Medicine for Oncology (Solid Tumor Portfolio, GI franchise) to lead biomarker strategies across our clinical programs.

You will oversee assay development, trial biomarkers, and regulatory contributions while mentoring teams and collaborating with external partners to accelerate oncology drug development.